Immune Checkpoint Inhibitor-Associated Myocarditis

Autor: Ali Yilmaz, Annalen Bleckmann, Michael Bietenbeck, Karin Klingel, Anca Florian, Claudia Meier, Georg Evers, Grigorios Chatzantonis
Rok vydání: 2020
Předmět:
0301 basic medicine
Myocarditis
PD-L
programmed death-ligand
ICI
immune checkpoint inhibitor
RR
reference range
Immune checkpoint inhibitors
medicine.medical_treatment
Case Report
Pembrolizumab
030105 genetics & heredity
Bioinformatics
Endomyocardial biopsy
03 medical and health sciences
0302 clinical medicine
Clinical Case
CMR
cardiac magnetic resonance
NSCLC
non–small cell lung cancer
irAE
LVEF
left ventricular ejection fraction
VT
ventricular tachycardia
polycyclic compounds
medicine
Diseases of the circulatory (Cardiovascular) system
CMR
Adverse effect
LV
left ventricular
LGE
late gadolinium enhancement
business.industry
PD
programmed death
medicine.disease
RC666-701
Non small lung cancer
pembrolizumab
ventricular tachycardia
MMF
mycophenolate mofetil
myocarditis
Cardiac monitoring
Cardiology and Cardiovascular Medicine
Cardiac magnetic resonance
business
hormones
hormone substitutes
and hormone antagonists
030217 neurology & neurosurgery
irAE
immune-related adverse event
Zdroj: JACC Case Reports
JACC: Case Reports, Vol 2, Iss 4, Pp 630-635 (2020)
ISSN: 2666-0849
DOI: 10.1016/j.jaccas.2019.12.047
Popis: Immune checkpoint inhibitors (ICIs) can induce immunity-related adverse events. We demonstrate the clinical use of cardiac magnetic resonance and endomyocardial biopsy in the diagnosis and subsequent monitoring of ICI-associated myocarditis, suggesting the need to establish and evaluate a cardiac monitoring protocol for patients under ICI therapy. (Level of Difficulty: Intermediate.)
Graphical abstract
Immune checkpoint inhibitors (ICIs) can induce immunity-related adverse events. We demonstrate the clinical use of cardiac magnetic resonance…
Databáze: OpenAIRE
Externí odkaz: